Document is current

Any future updates will be listed below

Correction to: Integrated Safety Analysis of Abrocitinib for the Treatment of Moderate-to-Severe Atopic Dermatitis From the Phase II and Phase III Clinical Trial Program

Crossref DOI link: https://doi.org/10.1007/s40257-021-00638-z

Published Online: 2021-10-13

Published Print: 2021-11

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark